Comprehensive Idiopathic Pulmonary Fibrosis Market Forecast 2025-2034: Growth Trends and Strategic Shifts

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Idiopathic Pulmonary Fibrosis Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The size of the idiopathic pulmonary fibrosis market has seen a significant increase over the past few years. The market is predicted to rise from a value of $4.15 billion in 2024 to $4.39 billion in 2025, with a compound annual growth rate (CAGR) of 5.6%. The growth during the historical period is linked to the rise in the aging population, scarcity of effective treatment alternatives, growing awareness of the disease, and developments in healthcare infrastructure.

Idiopathic Pulmonary Fibrosis Market Size Forecast: What's the Projected Valuation by 2029?
The market for idiopathic pulmonary fibrosis is predicted to undergo significant expansion in the forthcoming years. It's estimated to reach $5.74 billion by 2029, with a compound annual growth rate (CAGR) of 7.0%. Causes for this projected growth during the forecasted period include heightened research and development, the application of precision medicine, a rise in disease occurrences, progress in biomarker creation, and governmental support and funding. Emerging trends for this period are anticipated to be improvements in diagnostics, the rise of targeted therapies, the adoption of telemedicine and remote monitoring, combination treatments, and advancements in the field of lung transplantation.

View the full report here:
https://www.thebusinessresearchcompany.com/report/idiopathic-pulmonary-fibrosis-global-market-report

What Are the Drivers Transforming the Idiopathic Pulmonary Fibrosis Market?
The increasing occurrence of fibrotic disease is anticipated to propel the growth of the idiopathic pulmonary fibrosis market. Fibrotic diseases, also known as fibrosis, denote a range of medical conditions marked by an excessive creation and buildup of fibrous connective tissue in various organs or tissues of the body. Drugs for idiopathic pulmonary fibrosis assist in reducing lung fibrosis and inflammation by addressing numerous signaling pathways concerned with fibrosis. For instance, in December 2022, as per the American Lung Association, a US-origin lung association, nearly 207,000 individuals were affected in the United States, with close to 58,000 new cases of idiopathic pulmonary fibrosis diagnosed each year. This condition is more prevalent in men than women and tends to impact individuals above 50 years of age. Consequently, the escalating occurrence of fibrotic disease fuels the idiopathic pulmonary fibrosis market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12579&type=smp

What Long-Term Trends Will Define the Future of the Idiopathic Pulmonary Fibrosis Market?
The increasing emphasis on product innovation is a notable trend in the idiopathic pulmonary fibrosis market. Major players in the market are focusing on the development of innovative products as a strategy to cement their market position and achieve a competitive edge. For example, in May 2022, Sandoz, a firm based in Switzerland that produces generic and biosimilar medicines, introduced a generic variant of pirfenidone. This variation is the first AB-rated equivalent of Genentech's Esbriet, specifically formulated for the treatment of individuals afflicted with idiopathic pulmonary fibrosis (IPF). This prescription medication, taken orally, is now available to patients via specialty pharmacies, with eligible patients having the opportunity to avail of a USD 0 co-pay program.

Which Segments in the Idiopathic Pulmonary Fibrosis Market Offer the Most Profit Potential?
The idiopathic pulmonary fibrosis market covered in this report is segmented -

1) By Drug Type: Nintedanib, Pirfenidone, Other Drug Types
2) By Mode Of Action: Antifibrotic Agents, Tyrosine Kinase Inhibitors, Other Modes Of Action
3) By Route Of Administration: Oral, Parenteral
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Providers
5) By End Users: Hospitals And Clinics, Other End Users

Subsegments:
1) By Nintedanib: Indications, Dosage Forms, Administration Routes
2) By Pirfenidone: Indications, Dosage Forms, Administration Routes
3) By Other Drug Types: Specific Agents Or Classes, Emerging Therapies, Combination Therapies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12579&type=smp

Which Firms Dominate the Idiopathic Pulmonary Fibrosis Market by Market Share and Revenue in 2025?
Major companies operating in the idiopathic pulmonary fibrosis market include F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., Gilead Sciences Inc., Toray Industries Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Sun Pharmaceutical Industries Limited, Shionogi and Co. Ltd., Cipla Inc., Zydus Lifesciences Ltd., Chong Kun Dang Pharmaceutical Corp., Kyorin Pharmaceutical Co. Ltd., Galapagos NV, Veracyte Inc., Genentech Inc., FibroGen Inc., GNI Group Ltd., Pliant Therapeutics Inc., Pulmatrix Inc., Galimedix Therapeutics Inc., Avalyn Pharma Inc., MediciNova Inc., Liminal BioSciences Inc., Beijing Continent Pharmaceuticals Company, Galecto Inc.

Which Regions Offer the Highest Growth Potential in the Idiopathic Pulmonary Fibrosis Market?
North America was the largest region in the idiopathic pulmonary fibrosis market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the idiopathic pulmonary fibrosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12579

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.